40,000 Shares in Gilead Sciences, Inc. $GILD Acquired by Resolute Capital Asset Partners LLC

Resolute Capital Asset Partners LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,482,000. Gilead Sciences makes up approximately 2.5% of Resolute Capital Asset Partners LLC’s investment portfolio, making the stock its 11th largest position.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nissay Asset Management Corp Japan ADV raised its position in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company’s stock valued at $26,750,000 after purchasing an additional 14,009 shares in the last quarter. Golden State Wealth Management LLC raised its position in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 109 shares in the last quarter. Mufg Securities Americas Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $1,699,000. ASR Vermogensbeheer N.V. bought a new stake in Gilead Sciences during the 1st quarter valued at $11,688,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in Gilead Sciences by 4.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company’s stock valued at $32,827,000 after purchasing an additional 13,194 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the transaction, the chief financial officer directly owned 160,110 shares of the company’s stock, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock worth $9,339,230. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GILD shares. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research report on Friday, July 25th. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Finally, Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $115.39.

Gilead Sciences Stock Down 1.2%

Gilead Sciences stock opened at $114.77 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The business’s 50-day simple moving average is $112.51 and its two-hundred day simple moving average is $109.02. The company has a market cap of $142.41 billion, a PE ratio of 22.86, a PEG ratio of 0.71 and a beta of 0.33. Gilead Sciences, Inc. has a fifty-two week low of $75.91 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.